Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.
about
Citalopram versus other anti-depressive agents for depressionOptimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical PracticeEarly versus conventional switching of antidepressant: a post-hoc analysis of clinical trial data for major depressive disorder with moderate to severe pain symptoms.Gray matter increases in fronto-parietal regions of depression patients with aripiprazole monotherapy: An exploratory study.Dose Trends of Aripiprazole from 2004 to 2014 in Psychiatric Inpatients in KoreaMeta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorderSerotonin Receptor 2C -759C/T Polymorphism and Weight Change or Treatment Response to Mirtazapine in Korean Depressive Patients.Oral scopolamine augmentation for major depression.Atypical antipsychotics as a possible treatment option for irritable bowel syndrome.New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signalingPsychiatric symptoms in temporal lobe epilepsy with left mesial hippocampal sclerosis.Real-world determinants of adjunctive antipsychotic prescribing for patients with major depressive disorder and inadequate response to antidepressants: a case review studyEffects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.A chemical genetic approach identifies piperazine antipsychotics as promoters of CNS neurite growth on inhibitory substrates.Comparison of health-related quality of life among patients using atypical antipsychotics for treatment of depression: results from the National Health and Wellness Survey.Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability: Post Hoc Analysis of 2 Pivotal Clinical Studies.Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment.Aripiprazole in the treatment of Alzheimer's disease.Clinical issues in use of atypical antipsychotics for depressed patients.Do we need to consider ethno-cultural variation in the use of atypical antipsychotics for Asian patients with major depressive disorder?Management of chronic depressive patients with residual symptoms.Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.Omega-3 polyunsaturated fatty acids for major depressive disorder.The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder.Pramipexole augmentation in treatment-resistant major depressive disorder.Early switch strategy in patients with major depressive disorder.Can botulinum toxin improve mood in depressed patients?Relationship between symptoms of depression and agitation in nursing home residents with dementia.Neuroprotection by aripiprazole against β-amyloid-induced toxicity by P-CK2α activation via inhibition of GSK-3β.Criticisms of drugs in early development for the treatment of depression: what can be improved?
P2860
Q24202141-D0FBB37D-0E7C-4C66-B18E-551A17DA8B70Q26797416-50D3E6C9-7712-464D-B804-3C8C8455C3AEQ30576989-1E4C989B-AB75-44AF-85EA-0314D12241CEQ33590599-69E4B66C-F1B8-4856-BFC5-92DEADEE6D83Q33662847-AB517D38-A22D-4C58-8BF9-AA45F1A73B5DQ34010693-13682D1E-7E38-4E96-B550-09B9B61A2CDAQ34012293-333A7EBA-4BDD-44D6-858D-84B3C9C98D2EQ34318539-DEEFCBC8-7F95-46D2-A957-44EAF2AD25ABQ34333642-753ABB2C-204D-439A-B633-8692922A42ECQ34772251-BF96075A-8387-4D48-954C-986B138CD2CAQ35330714-4A56ACAF-C200-4984-ABFA-000C3F993CC6Q35666205-9C114AC4-820A-4D85-A798-6CE5FE692EB2Q36027225-DF0EEF8F-2ABA-4C0B-BB11-5388C8645418Q36059047-FC0D427B-505D-43E9-B83D-67029CF97DF8Q36138866-ACF5AB1A-348F-452C-A81C-2E9194C94217Q37665044-B6E36297-AF4A-47C7-919E-7115B08D30DCQ37947687-4CA88AF4-A320-42B6-86A6-BA34EE8F2305Q38076765-F5648F2D-4ADC-4217-B967-A69DF90919D6Q38109591-FF53FDE9-C5C5-4BD0-84BA-D051F57CF90CQ38109592-06C3EB85-EF33-4C6E-BFB9-6FFBD9E3C75EQ38109593-7C69D2B4-A284-4F97-ADA5-019849489EF9Q38125219-F78CAE84-7B6C-43FD-BC3B-EADA125078F7Q38148244-D66AE6F1-32B3-4F03-8D90-F848CEE21D50Q38674314-DF36B7DE-2394-4ADF-95E0-25D9093DE03DQ39301010-847A668A-7C60-4184-947B-F7A94AAADF7FQ39533915-D07CEC3D-C7AB-41BA-B77B-65043CF7B0F7Q39541450-F16B1E40-D72B-4C39-99E5-E51F49AF67B2Q43849399-182E8365-69F7-4381-A097-482D49BF3B2BQ47170401-D52FEF65-1FCB-435A-87D7-B603CCCFFD1FQ48148268-774EE809-BAC1-4809-80C2-0BCDB071FFD6
P2860
Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Aripiprazole as adjunctive the ...... ations of clinical trial data.
@ast
Aripiprazole as adjunctive the ...... ations of clinical trial data.
@en
type
label
Aripiprazole as adjunctive the ...... ations of clinical trial data.
@ast
Aripiprazole as adjunctive the ...... ations of clinical trial data.
@en
prefLabel
Aripiprazole as adjunctive the ...... ations of clinical trial data.
@ast
Aripiprazole as adjunctive the ...... ations of clinical trial data.
@en
P2093
P2860
P1433
P1476
Aripiprazole as adjunctive the ...... ations of clinical trial data.
@en
P2093
Andy Forbes
Ashwin A Patkar
Chi-Un Pae
P2860
P304
P356
10.2165/11538980-000000000-00000
P577
2011-02-01T00:00:00Z
P5875
P6179
1004975111